Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Pharmacodynamics of Rivaroxaban and Apixaban in Compensated Liver Cirrhosis
NCT04874428Phase 1Recruiting
- Sponsor
- Insel Gruppe
- Start
- May 2021
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of rivaroxaban and apixaban in thrombosis (2 arms), sponsored by Insel Gruppe. Primary endpoints: Area under the plasma concentration-time curve at 12 hours, Maximum plasma concentration at 12 hours and 3 more. Started May 2021; status: recruiting.
02
Drugs
rivaroxabanapixaban
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT04874428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04874428.